Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data

Background Clinicians have questioned whether any disorder involving seizures and neural antibodies should be called (auto)immune epilepsy. The concept of acute symptomatic seizures may be more applicable in cases with antibodies against neural cell surface antigens. We aimed at determining the probability of achieving seizure-freedom, the use of anti-seizure medication (ASM), and immunotherapy in patients with either constellation. As a potential pathophysiological correlate, we analyzed antibody titer courses. Methods Retrospective cohort study of 39 patients with seizures and neural antibodies, follow-up >= 3 years. Results Patients had surface antibodies against theN-methyl-d-aspartate receptor (NMDAR,n = 6), leucine-rich glioma inactivated protein 1 (LGI1,n = 11), contactin-associated protein-2 (CASPR2,n = 8), or antibodies against the intracellular antigens glutamic acid decarboxylase 65 kDa (GAD65,n = 13) or Ma2 (n = 1). Patients with surface antibodies reached first seizure-freedom (88% vs. 7%,P < 0.001) and terminal seizure-freedom (80% vs. 7%,P < 0.001) more frequently. The time to first and terminal seizure-freedom and the time to freedom from ASM were shorter in the surface antibody group (Kaplan-Meier curves:P < 0.0001 for first seizure-freedom;P < 0.0001 for terminal seizure-freedom;P = 0.0042 for terminal ASM-freedom). Maximum ASM defined daily doses were higher in the groups with intracellular antibodies. Seizure-freedom was achieved after additional immunotherapy, not always accompanied by increased ASM doses. Titers of surface antibodies but not intracellular antibodies decreased over time. Conclusion Seizures with surface antibodies should mostly be considered acute symptomatic and transient and not indicative of epilepsy. This has consequences for ASM prescription and social restrictions. Antibody titers correlate with clinical courses.

Automated summary

Patients with surface antibodies are more likely to achieve seizure freedom and require less long-term use of anti-seizure medication. Changes in antibody titers are closely related to clinical courses.